From GlobeNewswire: 2025-06-10 08:31:00

Neuronetics, Inc. is showcasing its commitment to clinical excellence and innovation in mental health care at the 13th Annual Clinical TMS Society Meeting in San Diego, CA. They will present data comparing NeuroStar’s Figure-8 coil to Brainsway’s H-coil for depression treatment. Additionally, a program by Greenbrook Mental Wellness Centers, a Neuronetics subsidiary, is exploring personalized qEEG-informed TMS therapy protocols. Neuronetics aims to optimize TMS efficacy and expand its use. NeuroStar Advanced Therapy System is FDA-cleared for MDD treatment and is backed by a large clinical data set. Greenbrook TMS Inc. offers NeuroStar Advanced Therapy and SPRAVATO® Nasal Spray for mental health disorders.



Read more at GlobeNewswire: Neuronetics Announces Clinical Presence at the 2025